NanoViricides, Inc
NanoViricides, Inc. is a clinical-stage biopharmaceutical company developing nanomedicine-based antiviral drugs using its licensed TheraCour platform. The company is focused on creating broad-spectrum therapies for multiple viral diseases, with its first candidate, NV-387, having completed Phase Ia/Ib safety and tolerability testing and moving toward Phase II efficacy trials.
Tilikausi 2026 · muutos edellisvuodesta
Kehitys 2021–2026
Liiketoiminta
Osuus liikevaihdostaDrug programs such as NV-387 that are being advanced through preclinical and clinical development for viral diseases.
Licensed nanomedicine technology used to design antiviral candidates against multiple virus families.
In-house and subcontracted capabilities for formulation, filling, finishing, and clinical trial supply.
Internal and outsourced preclinical, virology, toxicology, and regulatory development work.
Potential out-licensing, co-development, and partnership arrangements for antiviral programs.
Asiakkaat
NanoViricides does not currently have commercial customers or product revenue; its near-term counterparties are regulators, CROs, CMOs, and potential pharmaceutical partners. If programs succeed, the eventual buyers would be healthcare systems, physicians, and distributors purchasing approved antiviral drugs for specific viral indications. The company also seeks non-dilutive funding and licensing partners to support development before commercialization.
FDA-facing development work, clinical trial execution, and regulatory submissions needed to advance candidates toward approval.
External labs and CROs perform animal studies, virology testing, toxicology, biostatistics, and trial support.
CMOs may manufacture injectable clinical trial material when in-house capacity is not used.
Potential partners may fund, co-develop, or license antiviral programs for upfronts, milestones, and royalties.
Hospitals, physicians, and distributors would buy approved antiviral products if commercialization succeeds.
Strategia
The company’s strategy is to advance a platform of antiviral nanomedicines from discovery through cGMP manufacturing and clinical trials using as much in-house capability as possible. It aims to reduce development risk and cost by controlling formulation, characterization, and some manufacturing steps, while using CROs and external partners where needed. Management also intends to pursue licensing and co-development deals to obtain non-dilutive funding and broaden commercialization options.
The first candidate is the lead asset and the main path to proof of concept and eventual approval.
A broader pipeline can reuse the same technology and improve the chance of a commercial outcome.
Internal cGMP capability can lower costs, improve control, and reduce dependence on third parties.
The company has no revenue and needs external funding to support long development timelines.
Maantiede
NanoViricides is headquartered in Shelton, Connecticut and operates as a U.S.-based development-stage company. Its licenses are described as worldwide, and management has stated it intends to pursue co-development and licensing agreements in the U.S. and internationally. Because the company has no product revenue, geography currently matters more for R&D operations, regulatory pathways, and future partnering than for sales mix.
Riskit
NanoViricides is a development-stage company with no approved products, no revenue, and a continuing need for capital, so execution risk is high. Its business depends on successful preclinical and clinical results, regulatory approvals, and the ability to manufacture complex nanomedicines reliably at cGMP standards. Competition from larger antiviral developers, as well as the possibility that vaccines or alternative therapies reduce market size, also creates meaningful commercialization risk.
- No commercial products or revenueVaikutus: KriittinenTodennäköisyys: Korkea
The company is still in development and has not generated product sales, so it depends on future approvals and funding.
Kohdistuu: Entire business model
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Korkea
Lead candidates must prove safety and efficacy in humans before any commercialization can occur.
Kohdistuu: NV-387 and pipeline programs
- Capital raising and dilutionVaikutus: KorkeaTodennäköisyys: Korkea
Management states substantial additional capital will be needed to fund operations and trials.
Kohdistuu: Operating runway and shareholder dilution
- Manufacturing and cGMP executionVaikutus: KorkeaTodennäköisyys: Kohtalainen
Complex nanomedicine production under cGMP conditions is a known industry failure point.
Kohdistuu: Clinical supply and future commercialization
- Competitive and market substitution riskVaikutus: KeskitasoTodennäköisyys: Matala
Existing antivirals, vaccines, or superior therapies could reduce demand for the company’s candidates.
Kohdistuu: Target viral disease markets
Kirjanpito
Harkinnanvaraiset erätInternal and third-party development costs are expensed as incurred, which directly affects reported losses and comparability across periods.
Vaikutus: Main driver of operating loss
The company owns its campus, lab, and manufacturing assets, so utilization and project success affect recoverability.
Vaikutus: Could affect operating expense and asset values
Future upfront, milestone, royalty, or cost-sharing arrangements would require judgment on timing and allocation.
Vaikutus: Could materially affect future revenue pattern
Management’s treatment of lab, manufacturing, and trial-related costs influences reported earnings and asset balances.
Vaikutus: Affects loss recognition timing
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Nano Nuclear Energy Inc.
NNE · Electric Services
Vaxcyte, Inc.
PCVX · Biological Products, (No Diagnostic Substances)
Vir Biotechnology, Inc.
VIR · Biological Products, (No Diagnostic Substances)
Cocrystal Pharma, Inc.
COCP · Pharmaceutical Preparations
Enanta Pharmaceuticals, Inc
ENTA · Pharmaceutical Preparations
Enanta Pharmaceuticals is a U.S.-based biotechnology company focused on discovering and developing small-molecule drugs in virology and immunology.
Päivitetty: 24.9.2026